Lodestone Management Consultants' Clinical Trials Supply Management (CTSM) Solution Achieves SAP Certification

Lodestone Management Consultants' Clinical Trials Supply Management (CTSM) Solution Achieves SAP Certification as "Powered by SAP NetWeaver®"

Lodestone Management Consultants today announced the new software release 1.0 of its Clinical Trials Supply Management (CTSM) Add-On Suite®. The solution has achieved SAP certification as powered by the SAP NetWeaver® technology platform, providing more transparency and a reduction of overages in the complex and time-consuming clinical development process of which the clinical supply chain is a key component.

The SAP Integration and Certification Center (SAP ICC) has certified that Clinical Trials Supply Management 1.0 has achieved SAP certification as "Powered by SAP NetWeaver" as an ABAPTM Add-on 7.0 for the SAP Supply Chain Management (SAP SCM) application for integration with the SAP ERP 6.0 application.

Pharmaceutical, medical device and biotech industries (e.g., life sciences) must reduce their research and development (R&D) costs and time-to-market requirements to remain competitive in an increasingly complex environment. Lodestone has developed significant experience and expertise in CTSM from strategy definition to solution implementation.

With CTSM Add-On Suite 1.0, Lodestone provides the new software release integrated with SAP NetWeaver. It has been significantly enhanced in the following two areas:

Clinical demand planning, in order to increase clinical forecast accuracy
Packaging and distribution execution, in order to configure the many process variants that are required for the handling of investigational medical products in clinical trials
"Through the integration of Lodestone CTSM Add-On Suite and SAP NetWeaver, our customers can achieve a ‘win-win-win' through the use of the following: the best-in-class CTSM solution together with the technology platform from SAP and low total cost of ownership." said Jürgen Bauer, partner and Global Life Sciences Leader, Lodestone Management Consultants.

In addition, Lodestone, with a proven track record with many clients in life sciences industry, has joined the SAP® PartnerEdgeTM program as an SAP software solution partner. Through the program, Lodestone will now work closely with SAP to develop and certify the technical integration of its solutions with SAP software. Integrated partner applications, such as CTSM Add-On Suite for the life sciences industry, extend, complement and add value to SAP solutions, thereby helping mutual clients more successfully meet their business needs and drive strong results.

Lodestone is also a member of SAP EcoHub, a community-enabled online marketplace that makes it easy for customers to discover, evaluate and purchase solutions that complement their SAP applications, including CTSM Add-On Suite. Participation in SAP EcoHub provides Lodestone with a powerful new channel for reaching customers in an interactive community that integrates community input, user feedback, ratings and demos. Visitors of the SAP Ecohub can schedule a solution demo on SAP EcoHub with Lodestone or request more information at: https://www.sdn.sap.com/irj/ecohub/solutions/ClinicalTrialsSupplyMgmt.

Further information on the R&D Supply Chain consultancy services from Lodestone and the CTSM Add-On Suite can be viewed at www.lodestonemc.com/work/ctsm/.

About Lodestone Management Consultants

Lodestone Management Consultants is a global consulting firm, advising international companies on strategy and process optimization as well as IT transformation. Lodestone was founded in 2005 and has grown to 600 employees in 14 countries worldwide. Headquarters are in Zurich, Switzerland. Lodestone has a passion for excellence and is committed to delivery. For further information, please see www.lodestonemc.com.

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.